Novo's Wegovy Pill Beats Forecasts, Third Guidance Raise Tightens Race With Lilly
LLY sits 67% above its 52-week low of $850.51.
Summary
Novo Nordisk's oral Wegovy pill posted Q3 sales of 5.39 billion Danish crowns ($810 million), up 53% from Q2 and above the 4.62 billion consensus, and Novo raised full-year guidance for the third time, to a range of +2% to -2% from a prior 0% to 6% decline. Adjusted operating profit of 31.72 billion crowns and adjusted sales of 79.20 billion crowns both beat consensus. The read-through for Lilly is competitive rather than fundamental: Novo's oral franchise is gaining traction just as Lilly's own Foundayo pill is taking a growing share of new prescriptions, and Lilly's retatrutide already beat Ozempic in a late-stage head-to-head on October 28. Lilly's Q3, reported October 29, showed revenue up 39% to $24.4 billion with raised full-year revenue guidance, so the thesis is intact, but Novo's stabilization narrows the runway for Lilly to keep taking obesity share at the current pace.
At the time of this announcement, LLY was trading at $1,416.54 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.3T. The 52-week trading range was $850.51 to $1,449.68. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.